| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S80589-5mg买3赠1 |
99.30% | ￥120.00 |
9 | - | - | - | - |
|
S80589-10mg |
99.30% | ￥180.00 |
9 | - | - | - | - |
|
S80589-25mg |
99.30% | ￥280.00 |
8 | - | - | - | - |
|
S80589-50mg |
99.30% | ￥420.00 |
3 | - | - | - | - |
|
S80589-100mg |
≥99% | ￥630.00 |
货期：2-3天 | - | - | - | - |
|
S80589-200mg |
≥99% | ￥940.00 |
货期：2-3天 | - | - | - | - |
|
| 产品描述： | CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | IC50: 1.5 µM (Rho-pathway selective serum response element-luciferase reporter);LRRK2;Rho;Ras | ||||||||||||||||||||
| 体内研究： | CCG-1423 (0.15 mg/kg; i.p. once daily for two weeks) affects glucose tolerance and insulin levels in HFD-fed mice | ||||||||||||||||||||
| 参考文献： | 1. Evelyn CR, et al. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorg Med Chem Lett. 2010 Jan 15;20(2):665-72. 2. Jin W, et al. Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest. 2011 Mar;121(3):918-29. 3. Evelyn CR, et al. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther. 2007 Aug;6(8):2249-60. | ||||||||||||||||||||
| 溶解性： | DMSO : 100 mg/mL (219.90 mM; ultrasonic and warming and heat to 60°C) | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京